Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by valentinemassonon Aug 03, 2020 11:04pm
320 Views
Post# 31359363

Wind of change

Wind of change
 Seems upon us. James (Jim in the Vid) -loved the hand gestures at approx. 37 minute and 52 minute mark. Talk of reverse split: we have to realize that whatever it takes to list on Nasdaq - A bid of $3 US is required as well as 2 MMs as per regulations. 1 for 2 split: SP would have to be at $1.50 US. On the other side of the split, a 1:8 split means it would be at $0.375 cents US , to bring it to $3. Important to remember, Share price would increase exponentially according to the ratios given , and result in lesser shares available for shorting. Lesser shares , means future  NR , verbatim ; and hype would allow broader market interests, and with less shares the potential for growth exists in the hands of we, the shareholders. Remember Tilray a few years back? We have 2 institutional shareholders who bought in at 7 cents CDN. SONA and MIR have zero. Listen to the video , extract which tests are FDA acceptable , how the rules for acceptable testing have changed, and many of those early companies approved for EUA will never receive full approval. We are conducting tests that most recently as the bar has been raised higher , are acceptable.

   The potential is great and with Aristotle launching by years end , SZLS has seemingly taken the bull by the horns .

 Now and in the very near future is the time for James to shine. The market speaks with fluctuations as of late that prove frustrating. But the refusal to sell at this point may prove a good idea . Anyone in a CEO position, chooses at some point of their career to not bow out as someone who was never proven. We all have the need to leave some sort of legacy . Let`s hope that Jim can produce results and forever change a track record that many scoff at.

 Long SLZS.Glta.

 VM.
Bullboard Posts